CORD-19:932bcdd2f6c6d487386e8bf983e4874387771be1 / 13029-13407 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T93","span":{"begin":0,"end":378},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"To determine whether antibodies against beta-amyloid are also effective in human patients with Alzheimer's disease (AD), we participated in the Wyeth/Elan AN-1792 Phase 2A clinical trial, and included 30 patients with mild to moderate dementia who received two subsequent doses of pre-aggregated Abeta42 and QS-21 as an adjuvant in a randomized, placebo-controlled study design."}

{"project":"Epistemic_Statements","denotations":[{"id":"T25","span":{"begin":0,"end":378},"obj":"Epistemic_statement"}],"text":"To determine whether antibodies against beta-amyloid are also effective in human patients with Alzheimer's disease (AD), we participated in the Wyeth/Elan AN-1792 Phase 2A clinical trial, and included 30 patients with mild to moderate dementia who received two subsequent doses of pre-aggregated Abeta42 and QS-21 as an adjuvant in a randomized, placebo-controlled study design."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T93","span":{"begin":0,"end":378},"obj":"Sentence"}],"text":"To determine whether antibodies against beta-amyloid are also effective in human patients with Alzheimer's disease (AD), we participated in the Wyeth/Elan AN-1792 Phase 2A clinical trial, and included 30 patients with mild to moderate dementia who received two subsequent doses of pre-aggregated Abeta42 and QS-21 as an adjuvant in a randomized, placebo-controlled study design."}

{"project":"CORD-19-PD-HP","denotations":[{"id":"T82203","span":{"begin":95,"end":114},"obj":"Phenotype"},{"id":"T90740","span":{"begin":116,"end":118},"obj":"Phenotype"},{"id":"T47923","span":{"begin":235,"end":243},"obj":"Phenotype"}],"attributes":[{"id":"A40302","pred":"hp_id","subj":"T82203","obj":"http://purl.obolibrary.org/obo/HP_0002511"},{"id":"A78429","pred":"hp_id","subj":"T90740","obj":"http://purl.obolibrary.org/obo/HP_0002511"},{"id":"A29707","pred":"hp_id","subj":"T47923","obj":"http://purl.obolibrary.org/obo/HP_0000726"}],"text":"To determine whether antibodies against beta-amyloid are also effective in human patients with Alzheimer's disease (AD), we participated in the Wyeth/Elan AN-1792 Phase 2A clinical trial, and included 30 patients with mild to moderate dementia who received two subsequent doses of pre-aggregated Abeta42 and QS-21 as an adjuvant in a randomized, placebo-controlled study design."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T29500","span":{"begin":45,"end":52},"obj":"Disease"},{"id":"T40255","span":{"begin":95,"end":114},"obj":"Disease"},{"id":"T85487","span":{"begin":116,"end":118},"obj":"Disease"},{"id":"T31861","span":{"begin":235,"end":243},"obj":"Disease"},{"id":"T9052","span":{"begin":45,"end":52},"obj":"Disease"},{"id":"T21372","span":{"begin":95,"end":114},"obj":"Disease"},{"id":"T90412","span":{"begin":116,"end":118},"obj":"Disease"},{"id":"T35255","span":{"begin":235,"end":243},"obj":"Disease"}],"attributes":[{"id":"A16866","pred":"mondo_id","subj":"T29500","obj":"http://purl.obolibrary.org/obo/MONDO_0019065"},{"id":"A25315","pred":"mondo_id","subj":"T40255","obj":"http://purl.obolibrary.org/obo/MONDO_0004975"},{"id":"A7878","pred":"mondo_id","subj":"T85487","obj":"http://purl.obolibrary.org/obo/MONDO_0004975"},{"id":"A54859","pred":"mondo_id","subj":"T31861","obj":"http://purl.obolibrary.org/obo/MONDO_0001627"},{"id":"A68078","pred":"mondo_id","subj":"T9052","obj":"http://purl.obolibrary.org/obo/MONDO_0019065"},{"id":"A56962","pred":"mondo_id","subj":"T21372","obj":"http://purl.obolibrary.org/obo/MONDO_0004975"},{"id":"A57674","pred":"mondo_id","subj":"T90412","obj":"http://purl.obolibrary.org/obo/MONDO_0004975"},{"id":"A24326","pred":"mondo_id","subj":"T35255","obj":"http://purl.obolibrary.org/obo/MONDO_0001627"}],"text":"To determine whether antibodies against beta-amyloid are also effective in human patients with Alzheimer's disease (AD), we participated in the Wyeth/Elan AN-1792 Phase 2A clinical trial, and included 30 patients with mild to moderate dementia who received two subsequent doses of pre-aggregated Abeta42 and QS-21 as an adjuvant in a randomized, placebo-controlled study design."}